Evidence map›Paper›PMID 41048810›Full record

ArticleACS omega2025

A Multi-input Deep Learning Architecture for STAT3 Inhibitor Prediction.

Kairui Liang, Wenling Qin, Yonghong Zhang

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. STAT3 signaling inhibitors for cancer treatment.Trends in pharmacological sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kairui LiangChongqing Key Research Laboratory for Drug Metabolism, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Wenling QinChongqing Key Laboratory of Natural Product Synthesis and Drug Research, Chemical Biology Research Center, School of Pharmaceutical Sciences, Chongqing University, Chongqing 401331, China.ORCID https://orcid.org/0000-0002-5654-5785
Yonghong ZhangChongqing Key Research Laboratory for Drug Metabolism, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China.ORCID https://orcid.org/0000-0001-8574-9288

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Signal transducer and activator of transcription 3 (STAT3) is a critical factor involved in various physiological and oncogenic signaling pathways. Machine learning models are valuable tools for predicting or screening STAT3 inhibitors. However, the predictive performance and interpretability of existing models still require improvement. In this study, we introduce a fingerprint-enhanced graph (FPG) attention network model, which integrates sequence-based fingerprints and structure-based graph representations to predict STAT3 inhibitors. During the feature learning process, the FPG model converts sequence information into a fingerprint vector, while structural information is encoded into a separate vector using a graph attention network module. These two vectors are then concatenated and passed through a multilayer perceptron for molecular activity classification. Among 49 models with various representations and algorithm combinations, the FPG-based model achieved the best predictive performance, with an average area under the curve of 0.897 on the test set. Furthermore, the model outperformed existing prediction models for identifying STAT3 inhibitors. Additionally, fingerprint analysis and attention heatmaps, combined with SHAP algorithms, provided valuable insights into the structure-activity relationship of STAT3 inhibitors, enhancing model interpretability. To facilitate related research and applications, we developed a web service (STAT3 Pro: https://gzliang.cqu.edu.cn/software/Stat3Pro.html) for STAT3 inhibitor prediction.

Identifiers

PMID41048810
PMCPMC12489654

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.